Atrium Therapeutics, Inc.(RNA)
$6.98+0.34 (+5.12%)
RNA
Atrium Therapeutics, Inc. financials statements
$6.98
At close:+0.34 (+5.12%)
Want to see RNA full AI Analyst Report?
Atrium Therapeutics, Inc. (RNA) Ratios
25 Followers
Atrium Therapeutics, Inc. Ratios
RNA's free cash flow for Q3 2026 was $-25.78M. For the 2026 fiscal year, RNA's free cash flow was decreased by $-415.00K and operating cash flow was $-25.37M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.53 | 15.73 | 7.58 | 12.00 | 13.86 |
| Quick Ratio | 6.53 | 15.73 | 7.58 | 12.00 | 13.86 |
| Cash Ratio | 6.46 | 2.24 | 2.29 | 6.56 | 10.80 |
| Solvency Ratio | -1.07 | -2.30 | -1.64 | -2.84 | -2.54 |
| Operating Cash Flow Ratio | -0.98 | -3.07 | -1.48 | -2.63 | -3.20 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 201.78M | $ 1.40B | $ 483.52M | $ 562.22M | $ 364.99M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.02 | 0.02 | 0.03 |
| Debt-to-Equity Ratio | 0.02 | 0.00 | 0.02 | 0.02 | 0.03 |
| Debt-to-Capital Ratio | 0.02 | 0.00 | 0.02 | 0.02 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.34 | 1.10 | 1.26 | 1.11 | 1.12 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.21 | 0.06 | 0.13 | 0.20 | 0.28 |
| Net Debt to EBITDA | 3.48 | 0.57 | 0.75 | 1.86 | 2.63 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 78.02% | 84.96% | -984.95% |
| EBIT Margin | -412.64% | -3477.43% | -2464.41% | -1939.65% | -1265.83% |
| EBITDA Margin | -410.91% | -3451.96% | -2442.44% | -1924.61% | -1258.97% |
| Operating Profit Margin | -412.58% | -3477.43% | -2464.41% | -1939.65% | -1265.83% |
| Pretax Profit Margin | -412.64% | -2957.71% | -2219.87% | -1886.33% | -1265.38% |
| Net Profit Margin | -411.88% | -2957.71% | -2219.87% | -1886.33% | -1265.38% |
| Continuous Operations Profit Margin | -411.88% | -2957.71% | -2219.87% | -1886.33% | -1265.38% |
| Net Income Per EBT | 99.82% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 100.02% | 85.05% | 90.08% | 97.25% | 99.96% |
| Return on Assets (ROA) | -27.55% | -20.61% | -33.76% | -27.24% | -27.60% |
| Return on Equity (ROE) | -36.99% | -22.62% | -42.38% | -30.10% | -30.94% |
| Return on Capital Employed (ROCE) | -32.47% | -25.85% | -43.00% | -30.48% | -29.67% |
| Return on Invested Capital (ROIC) | -31.92% | -25.78% | -42.72% | -30.32% | -29.54% |
| Return on Tangible Assets | -27.55% | -20.61% | -33.76% | -27.24% | -27.60% |
| Earnings Yield | -30.38% | -9.93% | -32.12% | -15.03% | -11.98% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.39 | 1.11 | 2.38 | 10.36 |
| Payables Turnover | 0.00 | 0.00 | 0.24 | 0.30 | 36.06 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 3.38 | 0.60 | 0.57 | 0.61 | 0.60 |
| Asset Turnover | 0.07 | 0.01 | 0.02 | 0.01 | 0.02 |
| Working Capital Turnover Ratio | 0.00 | 0.01 | 0.02 | 0.02 | 0.03 |
| Cash Conversion Cycle | 0.00 | 945.31 | -1201.13 | -1066.93 | 25.10 |
| Days of Sales Outstanding | 0.00 | 945.31 | 329.23 | 153.34 | 35.22 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 1530.36 | 1220.26 | 10.12 |
| Operating Cycle | 0.00 | 945.31 | 329.23 | 153.34 | 35.22 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.40 | -2.70 | -1.63 | -2.61 | -2.29 |
| Free Cash Flow Per Share | -2.49 | -2.76 | -1.69 | -2.67 | -2.38 |
| Dividend Paid and CapEx Coverage Ratio | -28.46 | -42.58 | -28.16 | -48.27 | -25.35 |
| Capital Expenditure Coverage Ratio | -28.46 | -42.58 | -28.16 | -48.27 | -25.35 |
| Operating Cash Flow Coverage Ratio | -11.20 | -44.24 | -12.09 | -12.75 | -8.08 |
| Operating Cash Flow to Sales Ratio | -2.21 | -27.61 | -12.45 | -14.77 | -10.17 |
| Free Cash Flow Yield | -16.87% | -9.49% | -18.66% | -12.02% | -10.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.29 | -10.07 | -3.11 | -6.65 | -8.34 |
| Price-to-Sales (P/S) Ratio | 13.56 | 297.77 | 69.12 | 125.49 | 105.59 |
| Price-to-Book (P/B) Ratio | 1.22 | 2.28 | 1.32 | 2.00 | 2.58 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.93 | -10.54 | -5.36 | -8.32 | -9.99 |
| Price-to-Operating Cash Flow Ratio | -6.14 | -10.78 | -5.55 | -8.49 | -10.39 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 14.65 | 0.24 | -0.39 | -0.21 |
| Enterprise Value Multiple | 0.18 | -8.06 | -2.08 | -4.66 | -5.76 |
| Enterprise Value | -13.90M | 3.03B | 485.53M | 827.77M | 676.02M |
| EV to EBITDA | 0.18 | -8.06 | -2.08 | -4.66 | -5.76 |
| EV to Sales | -0.75 | 278.22 | 50.79 | 89.74 | 72.49 |
| EV to Free Cash Flow | 0.33 | -9.85 | -3.94 | -5.95 | -6.86 |
| EV to Operating Cash Flow | 0.34 | -10.08 | -4.08 | -6.07 | -7.13 |
| Tangible Book Value Per Share | 12.11 | 12.77 | 6.86 | 11.08 | 9.21 |
| Shareholders’ Equity Per Share | 12.11 | 12.77 | 6.86 | 11.08 | 9.21 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.09 | 0.10 | 0.13 | 0.18 | 0.23 |
| Net Income Per Share | -4.48 | -2.89 | -2.91 | -3.34 | -2.85 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.85 | 0.90 | 0.97 | 1.00 |
| Research & Development to Revenue | 2.89 | 27.86 | 19.98 | 16.31 | 10.85 |
| SG&A to Revenue | 2.24 | 7.91 | 5.67 | 4.09 | 2.81 |
| Stock-Based Compensation to Revenue | 0.41 | 4.71 | 4.00 | 2.94 | 1.83 |
| Income Quality | 0.83 | 0.93 | 0.56 | 0.78 | 0.80 |
Currency in USD

